RESUMO
The purpose of the current article is to encourage discussion among stakeholders about the viability and benefits of predoctoral prescriptive authority (RxP) training. The existing APA model curriculum for RxP training requires that such training is postdoctoral. However, predoctoral models are potentially viable and offer several distinct advantages: reducing the time and financial costs of training, attracting more applicants with a biopsychosocial orientation, and, as more individuals complete this training, enlarging the constituency for state prescriptive authority initiatives. Several possible predoctoral model curricula including the incorporation of a postdoctoral master's degree in clinical psychopharmacology are described within existing APA PhD program requirements, with suggested accommodations for PsyD programs. These are offered as alternatives to, rather than as replacements for, postdoctoral training for RxP.